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Abstract
Background: The incidence of congenital hypothyroidism (CH) differs significantly 
among different ethnicities and regions, and early differentiation of transient CH is 
important to avoid unnecessary prolonged treatment with L-T4.
Objective: To investigate the incidence of CH based on the newborn screening program 
in Guangxi Zhuang Autonomous Region, China, and to analyze the predictors that might 
allow for an early differentiation between permanent (P) and transient (T) CH.
Design and methods: Data from newborn screening program over a seven-year 
period (January 2009 to January 2016) at Guangxi Maternal and Child Health 
Hospital are analyzed. Blood samples were collected on filter paper between 3 and 
7 days after birth, and TSH level was measured by time-resolved fluorescence assay. 
Individuals with increased TSH (TSH ≥ 8 IU/L) levels detected by newborn screening 
were recalled for further evaluation. Serum TSH, FT3 and FT4 were determined by 
electrochemiluminescence assay using venous blood samples. Diagnosis of CH is based 
on elevated TSH levels (>10 IU/L) and decreased FT4 levels (<12 pmol/L). Patients with 
elevated TSH levels and normal FT4 levels were diagnosed as hyperthyrotropinemia. 
Permanent or transient CH was determined by using the results of thyroid function tests 
after temporary withdrawal of L-T4 therapy at approximately 2–3 years of age.
Results: Among 1,238,340 infants in the newborn screening program, 14,443 individuals 
were recalled for reevaluation (re-call rate 1.18%), 911 and 731 individuals were 
subsequently determined to have hyperthyrotropinemia and CH respectively; thus, a 
prevalence of 1:1359 and 1:1694 for hyperthyrotropinemia and CH. Of the 731 patients 
with CH, 161 patients were diagnosed with permanent CH (PCH), and 159 patients were 
diagnosed with transient CH (TCH), the other 411 patients are too young to determine 
their subtypes. Patients with PCH required an increasing dose of L-T4 during the first 
few years, whereas patients with TCH required a decreased dose of L-T4. The TSH levels 
at diagnosis and the dose of L-T4 used were significantly higher in PCH cases than in 
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transient cases. The FT4 levels at diagnosis were significantly lower in PCH cases than in 
TCH cases. The TSH levels at diagnosis, FT4 levels at diagnosis and L-T4 doses at 90 days 
were evaluated as predictors for differentiating PCH and TCH, and their accuracy at their 
respective optimal cutoffs were determined to be 60.6%, 66.7% and 93.9%, respectively.
Conclusions: The CH incidence in Guangxi Zhuang Autonomous Region is slightly higher 
(1:1694) compared to the worldwide levels (1/2000–1/4000). The PCH and TCH ratio 
is close to 1; thus, the estimated PCH incidence is 1/3388, which is similar to reported 
worldwide average incidence (1/3000). The L-T4 dose required at 90 days (>30 μg/day) 
has the highest predictive value for PCH. Earlier differentiation of PCH and TCH helps to 
determine appropriate treatment course.
Introduction
Congenital hypothyroidism (CH) is one of the most 
common causes of intellectual disability and growth 
retardation with worldwide incidence ranging from 
1:2000 to 1:4000 newborns (1, 2, 3). Newborn screening 
allows for early detection and treatment of CH, thus 
effectively preventing intellectual disability and short 
stature due to lack of thyroid hormone.
The incidence of CH differs significantly among 
different ethnicities and regions. For example, Zeinalzadeh 
and coworkers reported a CH prevalence of 1:666 (TSH 
cutoff level 10 IU/L) in East Azerbaijan, Iran (4), whereas 
a CH prevalence of 1:2591 (TSH cutoff level 10 IU/L) was 
reported in the Republic of Macedonia (5). Two previous 
studies reported the CH prevalence based on newborn 
screening programs in Han Chinese, and the incidence 
of CH was reported as 1:1678 (TSH cutoff level 9 IU/L) 
and 1:3009 (TSH cutoff level 10–15 IU/L), respectively 
in Zhejiang (6) and Shanghai (7) province. Little is 
known about the incidence of CH in Guangxi Zhuang 
Autonomous Region, which is located in South-west 
China with a population of distinct ethnic composition.
CH can be classified into PCH and TCH according to 
the clinical course. PCH refers to a persistent deficiency 
of thyroid hormone that requires lifelong treatment. TCH 
refers to a temporary deficiency of thyroid hormone at 
the early stage of life, but thyroid hormone production 
recovers to normal afterwards. Recovery to euthyroidism 
typically occurs in the first few months or years of life. 
The current guidelines recommend that all CH children be 
re-evaluated at the age of 3 years (8). Early differentiation 
of TCH is important to avoid unnecessary prolonged 
treatment with L-T4, and it is also helpful for predicting 
prognosis and alleviating families’ psychological 
burden. Thus, we investigated the CH incidence based 
on the newborn screening program in Guangxi Zhuang 
Autonomous Region, China and to analyze the factors 
that might allow an early differentiation between TCH 
and PCH.
Subjects and methods
1,238,340 newborns were screened for CH at the duration 
from January 2009 to January 2016 at the Newborn 
Screening Center of Guangxi, China. This center is 
responsible for half of the total population in Guangxi 
province. The coverage for newborn screening is 95.2% 
for this part of the country. The screening follows a 
standard screening protocol. Between 3 and 7 days after 
birth, 3 drops of heel blood were collected on a filter paper 
(S&S 903). The thyroid-stimulating hormone (TSH) level 
was measured by time-resolved fluorescence assay (Perkin 
Elmer).
The analytical sensitivity of TSH test was typically 
better than 0.002 IU/L. The accuracy of the TSH test was 
assessed using both intra- and inter-assay. Intra-assay 
coefficients of variation at TSH concentrations of 14.6, 
24.0 and 58.6 IU/L were 7.1, 6.3 and 7.0%, respectively, 
while the inter-assay coefficients of variation at the same 
TSH concentrations were 8.1, 9.0 and 7.8%, respectively. 
Subjects with increased TSH (TSH ≥ 8 IU/L) levels were 
contacted and re-evaluated. Pre-term (<37 weeks gestation) 
and low-birth-weight infants (<2000 g) underwent a 
second mass screening one month after birth, when 
their body weight reaches 2500 g, even if data in the first 
screening at age 3–7 days was within the normal range.
The confirmatory test was carried out between 7 
and 28  days after birth by electrochemiluminescence 
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assay (Cobas e601, Roche Diagnostics) with venous 
blood samples. The test results were compared to age-
specific reference as included in Supplementary Table 1 
(see section on supplementary data given at the end of 
this article). Diagnosis of CH is based on elevated TSH 
levels (>10 IU/L) and decreased FT4 levels (<12 pmol/L). 
Patients with elevated TSH levels and normal FT4 
levels were diagnosed as hyperthyrotropinemia (HT). 
Thyroid ultrasonography and 99mTc scintigraphy were 
performed during the neonatal period before treatment. 
L-T4 replacement therapy started after the diagnosis of 
CH, and the dose was adjusted according to the serum 
TSH and FT4 levels. The target serum FT4 level should 
be >50% of the normal range by age. The target for 
TSH level should be within the normal range by age. 
Permanent CH was determined by temporary withdrawal 
of L-T4 therapy at approximately 2–3 years of age. After 
one month of discontinuation of L-T4 treatment, TSH 
and FT4 levels were measured in venous blood sample. 
Individuals who showed contiguous dependency on 
L-T4 were diagnosed with permanent CH. These children 
were then repeatedly evaluated at regular intervals for 
1–1.5 years to monitor thyroid function. Those who did 
not need contiguous L-T4 therapy were diagnosed with 
transient CH. The study was approved by the Medical 
Ethics Committee of Guangxi Maternal and Child 
Health Hospital. Informed consent was obtained from 
the parents of the patients.
Statistical analysis
The data were analyzed using R software. Qualitative 
variables were compared using the Fisher test and 
quantitative variables were compared by t-test. All 
P values were two-sided with P < 0.05 being considered 
as significant. A receiver-operating characteristic (ROC) 
curve analysis was performed to identify the optimal 
cutoff values of predictor, which were able to distinguish 
between PCH and TCH. The best cutoffs were defined by 
the highest Youden index ((specificity + sensitivity)−1).
Results
During the study period, 1,238,340 newborns were 
screened. A skewed gender ratio was noticed in this 
population: 667,676 (53.9%) were male and 570,664 
(46.1%) were female. The female:male ratio was 1:1.17. 
80% of samples were taken from neonates at 3–5  days 
Table 1 Distribution of serum TSH levels among screened 
newborns (n = 12,38,340).
Distribution of TSH levels (IU/L) N %
0–4.9 11,40,493 92.1
5–7.9 81,062 6.5
8–9.9 9805 0.8
10–19.9 6109 0.5
≥20 871 0.1
Total 12,38,340 100
Figure 1
Variation of the TSH levels and positive rate based on the timing of newborn screening sampling.
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after birth. 97% of the neonates were screened within 
the first two weeks after birth. The distribution of serum 
TSH levels among screened newborns is shown in Table 1. 
We plotted the mean TSH levels and the positive rates 
from days 3 to day 14 and observed a concomitant decline 
of TSH levels and screening positive rates, but a significant 
improvement in confirmed positive rates (Fig. 1).
The mean TSH level at newborn screening in all 
measured samples was 2.3 ± 3.2 IU/L. The mean birth 
weight was 3113.1 ± 438.9 g and the mean gestation was 
38.8 ± 1.6  weeks. Overall, 14,443 neonates (1.18%) were 
detected to have high TSH levels in the first and second 
dry samples and were recalled for confirmatory test. 
The confirmatory test revealed normal FT4 levels and 
elevation of TSH in 911 neonates. These newborns were 
diagnosed as HT. 731 were diagnosed as CH with elevation 
of TSH levels and decreased FT4 levels. The incidence of 
CH and hyperthyrotropinemia was 1/1694 and 1/1359, 
respectively. The significant differences between HT and 
CH regarding TSH (Fig.  2A) and FT4 levels at diagnosis 
(Fig. 2B) are expected based on the definition. The analysis 
also revealed that more females are diagnosed with CH and 
more males are diagnosed with HT (Fig.  2E). Compared 
with individuals with HT, significantly more individuals 
with CH had abnormal thyroid morphology (Fig.  2F). 
There were no statistical differences between HT and CH 
regarding weight (Fig. 2C) and gestational weeks (Fig. 2D).
Among neonates with CH, 360 (49.2) were male and 
371 (50.8) were female (female:male ratio 1.03:1). The 
prevalence of CH among male and female neonates was 
1:1855 and 1:1538, respectively, and the difference was 
statistically significant (P = 0.012). The mean TSH level at 
diagnosis of CH neonates was 83.51 ± 26.84 IU/L. The mean 
birth weight of CH neonates was 3158.6 ± 775.6 g and the 
mean gestation was 38.9 ± 1.6  weeks. The birth weight 
and gestation weeks are not different in CH neonates in 
comparison to non-CH neonates. 57,981 of all newborns 
and 52 of the 731 CH cases were pre-term babies, and 
10,509 of all newborns and 12 of the 731 CH had low 
birth weight. The CH prevalence are significantly higher 
among pre-term (P < 0.002) and small for gestational age 
newborns (P < 0.019) compared with full-term newborns 
and norm birth weight newborns.
Of the 731 patients with CH, 161 patients were 
diagnosed as PCH and 159 patients were diagnosed as 
TCH, the PCH-to-TCH rate was about 1:1. The other 
411 patients are too young to withdraw L-T4 therapy, so 
we cannot determine their clinical phenotype. There were 
statistical differences between PCH and TCH regarding 
TSH levels at diagnosis (Fig.  3A), FT4 levels at diagnosis 
(Fig. 3B) and thyroid morphology composition (Fig. 3F). 
There were no statistical differences between PCH and 
TCH regarding gestation weeks (Fig. 3D), weight (Fig. 3C) 
and gender composition (Fig. 3E).
Figure 2
The clinical differences between HT and CH: TSH levels at diagnosis (A), FT4 levels at diagnosis (B), weight (C), gestational weeks (D), gender composition 
(E) and thyroid morphology (F).
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The individual doses and average dose of L-T4 at 
different age of newborns with PCH and TCH were 
shown in Fig.  4A and B, respectively. It is obvious that 
the PCH patients require a higher dosage and longer 
treatment duration. At the age of 900  days, 29.6% of 
TCH patients were treated with an average L-T4 dose of 
7.8 μg/day, whereas 100% of PCH patients were treated 
with an average dose of 38.9 μg/day.
The dependence on L-T4 showed a significant 
difference between PCH and TCH. To further evaluate the 
effectiveness of using L-T4 as a predictor, we performed 
ROC curve analysis at different times after diagnosis. 
The differentiating power increases at a later time point 
(Fig.  5A). The L-T4 doses used at 90  days is a relatively 
better predictor taking into account of early diagnosis, 
the area under the curve (AUC), sensitivity and specificity 
(Supplementary Table 2).
We also evaluated the effectiveness for differentiating 
PCH and TCH using TSH levels at diagnosis, FT4 levels at 
diagnosis and L-T4 doses at 90  days (Fig.  5B). Based on 
the ROC curve analysis, we determined the optimal cutoff 
values for predicting CH subtypes: The TSH levels at 
diagnosis was set at 97.1 IU/L, which yielded a sensitivity 
of 84.56% and a specificity of 52.94%, with the AUC at 
0.6889; the L-T4 doses at 90  days was set at 30 μg/day, 
which yielded a sensitivity of 58.09% and a specificity 
of 78.68%, with the AUC at 0.7220 and the value of FT4 
levels at diagnosis was set at 4.6 pmol/L, which yielded a 
sensitivity of 60.29% and a specificity of 69.85%, with the 
AUC at 0.6690.
To further assess the accuracy of the cutoffs for 
differentiating PCH and TCH determined by retrospective 
patient cohort, we used 33 prospective patients 
subsequently (Supplementary Table  3), who were 
identified with PCH or TCH from the total 731 CH cases 
during the process of manuscript preparation. As a result, 
the accuracy of predicting the CH subtypes are 60.6, 
66.7 and 93.9% using the cutoff values of TSH levels at 
diagnosis, FT4 levels at diagnosis and L-T4 doses at 90 days 
respectively. The L-T4 doses at 90 days is the best predictor 
of high accuracy.
Discussion
In this study, over 1.2 million newborns from Guangxi 
Zhuang Autonomous Region, China were screened for 
CH using a standard procedure with 8 IU/L as a cutoff 
value for TSH. As a result, 1.18% neonates were recalled 
for confirmatory test. This re-rate is higher than that 
of Mexico (0.15%) (9), Brazil (0.21%) (10), Netherlands 
(0.18%) (11) and Thailand (0.24%) (12), but lower than 
that of Iran (1.76%) (13), Turkey (7.2%) (14), India (1.39%) 
(15) and Bahrain (4%) (16).
The confirmed CH incidence is 1/1694 in this 
population. It is known that the incidence of CH could 
Figure 3
The clinical differences between TCH and PCH: TSH levels at diagnosis (A), FT4 levels at diagnosis (B), weight (C), gestational weeks (D), gender 
composition (E) and thyroid morphology (F).
This work is licensed under a Creative Commons 
Attribution-NonCommercial 4.0 International 
License.
Research C Fu, S Luo, Y Li et al. The predictors of permanent 
and transient CH
En
d
o
cr
in
e 
C
o
n
n
ec
ti
o
n
s
6:931931–934
DOI: 10.1530/EC-17-0289
http://www.endocrineconnections.org © 2017 The authors
Published by Bioscientifica Ltd
vary significantly from one ethnic group to another (1/370 
(17) to 1/10,000 (18)). Currently, the overall incidence of 
CH in Chinese population is not known, two previous 
studies based on populations in Zhejiang and Shanghai 
provided the incidences for Han Chinese as 1:1678 and 
1:3009, respectively. Guangxi Zhuang Autonomous Region 
is dominated with Zhuang minority, a distinct ethnic 
group from Han. Our study revealed that the incidence 
of CH among newborns in Guangxi Zhuang Autonomous 
Region is similar to that of Han Chinese in Zhejiang (6) 
and slightly higher than the average worldwide incidence 
(1/2000–1/4000) (1, 2, 3).
We have used a relative low cutoff value of TSH in 
this newborn screening program. 97% of the screening 
test was done within 3–14 days of life. For the first time, 
we plotted the mean TSH levels in the newborns period 
based on a large cohort of population and noticed a rapid 
decrease of TSH level in the first several days (Fig.  1). 
Noticeably, the positive screening rates also showed 
a similar decline. More importantly, the confirmed 
positive rates or false-positive rate also correlated with 
the average level of TSH at different days after birth. 
This finding challenged the validity of using one cutoff 
value of TSH for newborn CH screening at any days 
after birth. Further study can help to determine the 
right cutoff value for samples collected at different days 
after birth.
Recent studies suggest that the TSH levels, weight, 
gender, FT4 levels, gestational weeks and the thyroid 
morphology may correlate with the etiology of CH (19, 20, 
21). In our study, there were statistical differences between 
HT and CH regarding TSH levels, gender composition, 
FT4 levels and thyroid morphology composition. There 
were also statistical differences between PCH and TCH 
regarding the TSH levels, FT4 levels and the thyroid 
morphology, but no significant differences in gestation 
weeks, gender and weight were found between the two 
groups. It demonstrated the correlation between the three 
Figure 4
The doses of L-T4 used for CH patients at different age (black line for TCH and red line for PCH).
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factors (TSH levels, FT4 levels and thyroid morphology) 
and hypothyroidism.
Nearly all screening programs report a female 
preponderance among CH patients, often approaching a 
2:1 female-to-male ratio (1, 5). In our study, this ratio was 
1.03:1. The difference may be caused by the population 
gender bias among screened newborns (male:female 1.17) 
and etiological diversity of CH in different ethnic groups.
The PCH-to-TCH rate in our CH patients is bout 1:1. 
It is similar to that recently reported by other authors, 
who found rates ranging from 38 to 46% (19, 21, 22). 
Therefore, according to our and other authors’ results, 
more than one-third of the infants diagnosed with CH by 
neonatal screening will not require lifelong L-T4 therapy, 
and reliable markers that would allow earlier detection of 
TCH might be useful.
Treatment plan and prognosis differ significantly for 
patients with PCH or TCH. Often, it is not known what 
CH subtype each newborn-screen-positive patient has 
until L-T4 withdrawal at approximately 2–3 years of age. It 
is beneficial to have an earlier differentiation. In the past 
few years, several studies (19, 20, 21, 23, 24, 25, 26, 27, 28, 
29) tried to identify the factors that could allow an early 
discrimination between the cases with either P or T CH. In 
a study conducted by Unuvar and coworkers (19), T4 dose 
required to maintain a euthyroid state was the parameter 
that distinguished between TCH and PCH. Rabbiosi and 
coworkers (21), in a study conducted in Italy, reported 
major risk factors for PCH were prematurity, thyroid 
hypoplasia at diagnosis, first-degree familial history of 
goiter/nodules and high L-T4 requirements at follow-up. 
Hashemipour and coworkers, in a study conducted in 
Iran, reported PCH was associated with higher initial 
TSH and T4 levels than TCH. Skordis and coworkers (27) 
stated that L-T4 requirements >4.9 μg/kg/day at 12 months 
or >4.27 μg/kg/day at 24 months are highly suggestive of 
PCH; L-T4 requirements <1.7 μg/kg/day at 12 months or 
<1.45 μg/kg/day at 24  months are highly suggestive of 
TCH. Messina and coworkers (20) reported the initial 
measurements of the serum TSH level and the required 
doses of L-T4 therapy for maintaining normal thyroid 
hormone levels, growth and development may have a 
predictive role for differentiating PCH from TCH.
So far, although a few studies have been conducted 
with the purpose of determining how best to discriminate 
between cases with either TCH or PCH before the age 
of 3  years, the evolution of CH remains difficult to 
predict, mainly due to the lack of large-scale, long-term 
and in-depth studies. In our study, we evaluated the 
effectiveness using L-T4 dose, as well as TSH and FT4 levels 
at diagnosis as predictors for an early differentiation 
using so far the largest cohort of patients. Using multiple 
statistical methods, we found that children with a higher 
initial L-T4 dose and requiring increasing doses of L-T4 
during the first few years of treatment are likely to have 
PCH. Conversely, patients with a lower initial L-T4 dose 
Figure 5
(A) The ROC curve L-T4 doses at different time after diagnosis; (B) the ROC curve of TSH levels at diagnosis, L-T4 doses 90 days after diagnosis and FT4 
levels for predicting PCH and TCH.
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and requiring decreasing doses are likely to have TCH. 
High TSH levels and low FT4 levels at diagnosis were 
found to be significant predictors for PCH. The L-T4 doses, 
however, are the best independent predictor. An L-T4 
dose requirement at 90 days >30 μg/day demonstrated an 
accuracy of 93.9% for our prospective cohort.
In conclusion, the incidence of CH and 
hyperthyrotropinemia among newborns in Guangxi 
Zhuang Autonomous Region, China was 1/1694 and 
1/1359, respectively. The permanent CH and transient 
CH ratio is close to 1; thus, the estimated PCH incidence 
is 1/3708. There were statistical differences between 
hyperthyrotropinemia and CH regarding TSH levels, 
sex, FT4 levels and thyroid morphology; there were also 
statistical differences between PCH and TCH regarding the 
same four factors. Children with CH requiring increasing 
L-T4 doses during the first years of treatment are at risk 
for PCH; children with CH demonstrating decreased L-T4 
dependency to maintain normal TSH values over time are 
likely to have TCH. An L-T4 dose requirement at 90 days 
>30 μg/day is highly suggestive of PCH.
Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/10.1530/
EC-17-0289.
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